Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 13, 2012

Janssen Taps Genmab for Bispecific Antibody Platform

  • Janssen Biotech is making a $3.5 million up-front payment to Genmab to access the latter’s DuoBody platform for the development of bispecific antibodies against multiple target combinations. The deal follows just six weeks after Genmab inked a DuoBody partnership with Novartis.

    Under terms of the latest collaboration with Janssen, the latter will fully fund all Genmab’s research on up to 10 DuoBody programs. The firm could earn up to another $175 million in potential milestone and license payments for each product, plus future sales royalties.

    “Since the introduction of our DuoBody platform in 2010, we have believed in its potential to become the preferred technology for next-generation bispecific antibody therapeutics,” comments CEO Jan van de Winkel, Ph.D. “Today’s announcement is another indicator that the pharmaceutical industry recognizes our leadership in the therapeutic antibody field.”

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »